Join to View Full Profile
Dana-Farber Cancer Institute450 Brookline AveBoston, MA 02215
Phone+1 617-632-3000
Dr. Lynce is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
MedStar Health Georgetown University/Washington Hospital CenterFellowship, Hematology and Medical Oncology, 2011 - 2014- MedStar Health/Georgetown-Washington Hospital CenterResidency, Internal Medicine, 2008 - 2011
Certifications & Licensure
MA State Medical License 2020 - 2025
DC State Medical License 2008 - 2020
American Board of Internal Medicine Medical Oncology
Clinical Trials
- OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease Start of enrollment: 2018 May 21
- TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer Start of enrollment: 2019 Apr 17
Publications & Presentations
PubMed
- Serum analytes as predictors of disease recurrence and the duration of invasive disease-free survival in patients with triple negative breast cancer enrolled in the OX...Nicole J Toney, Megan T Lynch, Filipa Lynce, Candace Mainor, Claudine Isaacs
Journal for Immunotherapy of Cancer. 2025-04-23 - Oncotype DX Recurrence Score and Germline BRCA Variants in Patients with HR-Positive/HER2-Negative Early Breast Cancer: A Retrospective Observational Study.Stefania Morganti, Rabia A Khan, Luis C Berrocal-Almanza, Miguel Miranda, Linlin Luo
Oncology and Therapy. 2025-04-15 - Development of a Multi-Institutional Dataset to Validate a Novel Inflammatory Breast Cancer Diagnostic Score.Filipa Lynce, Samuel M Niman, Megumi Kai, Sean Ryan Ma, Elizabeth Troll
Journal of the National Cancer Institute. 2025-03-31
Journal Articles
- Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy with Disease Recurrence in Patients with Triple-Negative Breast CancerRita Nanda, Carla Falkson, Filipa C Lynce, Claudine Isaacs, Marcelo Blaya, Elisavet Paplomata, Radhika Walling, Reshma Mahtani, Tarah J Ballinger, Kathy D Miller, Brya..., JAMA Oncology
Authored Content
- Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy with Disease Recurrence in Patients with Triple-Negative Breast CancerJuly 2020
Press Mentions
Inflammatory Breast Cancer Grant Allows Two Researchers to Test a New Tool for Diagnosing the Aggressive SubtypeMay 31st, 2022
Dr. Lynce on FDA Approval of Atezolizumab/Nab-Paclitaxel in TNBCFebruary 11th, 2020
Data Presented on PI3K Pathway Alterations at SABCS 2019December 10th, 2019- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
